August 14, 2019
FDA Approves New Treatment for Highly Drug-Resistant Forms of Tuberculosis
Pretomanid, developed by the non-profit TB Alliance, has received U.S. approval in combination regimen with bedaquiline and linezolid for people with XDR-TB or treatment-intolerant/non-responsive MDR-TB
July 18, 2019
Statement on TB and HIV Coinfection Ahead of IAS2019
We must work together if we hope to end HIV and TB
June 25, 2019
TB Alliance Names Eugene Sun as Senior Vice President for Research and Development
Executive Brings more than 25 Years’ Experience Overseeing Research and Product Development
June 18, 2019
New Milestone for Children with Tuberculosis Reached as One Million Treatments of Child-Friendly Medicines are Ordered
The improved treatments have now been procured by 93 countries, which represent 75% of estimated childhood TB burden globally
June 12, 2019
Mitchell Warren Elected President of TB Alliance Stakeholders Association, Joins Board of Directors
Global health and HIV/AIDS leader brings extensive experience in advancing critical global health innovations
June 5, 2019
German Federal Ministry of Education and Research Invests in New TB Treatments
TB Alliance receives a €10 million funding commitment for the development of faster and better tuberculosis treatments
May 22, 2019